Recursion, Roche, and its Genentech subsidiary have unveiled a whole-genome map of specialized microglial immune cells that they plan to use toward revealing significant new targets in ...
TipRanks on MSN
Fate Therapeutics Reports Promising Phase 1 Trial Results
On October 26, 2025, Fate Therapeutics announced promising results from a Phase 1 clinical trial of its FT819 CAR T-cell therapy for systemic lupus erythematosus (SLE), presented at the ACR ...
Globe Investor value reports provide a daily price target for more than 9,000 stocks on the TSX, Nasdaq, and NYSE. Used by Bay Street pros, advisors and Canadians who invest on their own, they help ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback